Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations

Keywords

Rivaroxaban, Apixaban, Dabigatran, Medicine, Marketing authorization

References

• Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndromeUmroh Nadhiroh — 2010
• Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and HaemostasisTrevor Baglin, Andreas Hillarp, Armando Tripodi — 2013
• The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban‐treated patients: results of an in vitro studyArmando Tripodi, Veena Chantarangkul, C. Guinet — 2011
• The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).Paul Reilly, Thorsten Lehr, Sebastian Haertter — 2014
• Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.Charles Frost, Sunil Nepal, Jessie Wang — 2013
• Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trialKarl‐Heinz Liesenfeld, Thorsten Lehr, C. Dansirikul — 2011
• Influence of dabigatran and rivaroxaban on routine coagulation assaysEls Bailleul, Bernard Châtelain, Anne Demulder — 2014
• Performance of coagulation tests in patients on therapeutic doses of rivaroxabanE. M. Hawes, Allison M. Deal, Dorothy M. Adcock — 2014
• Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assaysClaire Flaujac, Xavier Delavenne, Sara Quenet — 2013
• Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assaysAndreas Hillarp, Fariba Baghaei, Inger Fagerberg Blixter — 2011
• Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent resultsVittorio Pengo, L. Crippa, Anna Falanga — 2012
• Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stentingJohn W. Eikelboom, Peter B. Berger, David R. Holmes — 2011
• Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitorRichard C. Becker, Hongqiu Yang, Yuchen Barrett — 2011
• Model-Based Exposure–Response Analysis of Apixaban to Quantify Bleeding Risk in Special Populations of Subjects Undergoing Orthopedic SurgeryTarek A. Leil, Chris Frost, Xueyan Wang — 2014
• Rivaroxaban and false positive lupus anticoagulant testingZane Kaplan, Jenny Butler, Erica Malan — 2010
• Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatranJoachim Stangier, Martin Feuring — 2012
• Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross‐sectional pharmacodynamic study based on peak and trough plasma levelsE. M. Hawes, Allison M. Deal, D. Funk‐Adcock — 2013
• Diffuse alveolar hemorrhage associated with dabigatran.K. Yokoi, Kikuo Isoda, Toyokazu Kimura — 2012
• Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic SurgeryWolfgang Mueck, Bengt I. Eriksson, Kenneth A. Bauer — 2008
• Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: Implications for emergency surgery and resuscitationMartine Wolf, Lilia Soufir, Arnaud Galbois — 2012

Cited by

• Periprocedural Management of Direct Oral Anticoagulants Should Be Guided by Accurate Laboratory TestsYulkarnain Harahab Hartini — 2016
• Dose tailoring of dabigatran etexilate: obvious or excessive?Jonathan Douxfils, François Mullier, Jean-Michel Dogné — 2015
• Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical PracticeJulie Kalabalik, Gail B. Rattinger, Jesse Sullivan — 2015
• Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future PerspectivesSteen Husted, Freek W.A. Verheugt, Willemijn Comuth — 2015
• Safety of apixaban for venous thromboembolism prophylaxis: the evidence to dateVladimir Trkulja — 2016
• Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or uselessJonathan Douxfils, Lionel Pochet, Sarah Lessire — 2016
• Lupus-anticoagulant testing at NOAC trough levelsFranz Ratzinger, Mona Lang, Sabine Belik — 2016
• Monitoring anticoagulant therapy with new oral agents.Allan Ramos-Esquivel — 2015
• An update on laboratory measurements of Dabigatran: Smart specific and calibrated dedicated assays for measuring anti-IIa activity in plasma.Jean Amiral, Claire Dunois, Cédric Amiral — 2016
• Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform studySophie Testa, Cristina Legnani, Armando Tripodi — 2016
• Reply to Dr Lessire et alJames D. Douketis, Sam Schulman, Summer Syed — 2016
• Reversal agents of non-vitamin K dependent anticoagulants: a rapid review of the changing horizonSupreet Kaur, Abhishek Kumar, Robert G. Lerner — 2016
• Clinical pearls: Laboratory assessments of direct oral anticoagulants (DOACS)Robert C. Gosselin, Jonathan Douxfils, Dorothy Adcock — 2017
• Use Your EYESMassimiliano Carassiti, Romualdo Del Buono, Felice Eugenio Agrò — 2016
• Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin BridgingSarah Lessire, Jonathan Douxfils, Lionel Pochet — 2018
• Development of an UHPLC-UV-Method for Quantification of Direct Oral Anticoagulants: Apixaban, Rivaroxaban, Dabigatran, and its Prodrug Dabigatran Etexilate in Human SerumSebastian Boehr, Ekkehard Haen — 2017
• A REVIEW ON NOVEL ORAL ANTICOAGULANTSK. Krishna Kumar, K. Jayapraksah, L Panayappan — 2016
• Non-vitamin-K oral anticoagulants and laboratory testing: now and in the futureTomas Salmonson, Jean‐Michel Dogné, Heidi Janssen — 2016
• Laboratory Assessment of Direct Oral AnticoagulantsRobert C. Gosselin, Jonathan Douxfils — 2017
• Minimisation of Bleeding Risks Due to Direct Oral AnticoagulantsOvidiu Vornicu, Anne‐Sophie Larock, Jonathan Douxfils — 2016

Related papers

• Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic SurgeryAnne R. Bass — 2015
• Expanding use of new oral anticoagulantsJeffrey I. Weitz — 2014
• Tissue Factor-Mediated Activation of the Prothrombin Complex Concentrate (PCC) is Differently Inhibited by Dabigatran, Rivaroxaban, and ApixabanNasiredin Sadeghi, Daniel Kahn, Walter Jeske — 2013
• [Guidelines of Czech Association for Thrombosis and Haemostasis of the Czech Medical Association of J. E. Purkyně for safety treatment with new oral anticoagulants (NOAC) - dabigatran etexilate, apixaban and rivaroxaban].J Kvasnička, Miroslav Penka, Tomáš Kvasnička — 2015
• Practical management of new oral anticoagulants after total hip or total knee arthroplastyWolfgang Klauser, M. Dütsch — 2013
• Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxabanThorsten Steiner, Michael Böhm, Martin Dichgans — 2013
• A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation.James W. Wisler, Richard C. Becker — 2012
• Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.2013
• Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixabanAdewale Fawole, Hamed Daw, Mark Crowther — 2013